HF
CTNM

HRT Financial’s Contineum Therapeutics CTNM Stock Holding History

HRT Financial’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-22,170
Closed -$289K – 5560
2026
Q1 		$289K Buy
+22,170
New +$297K ﹤0.01% 2907
2024
Q4 		– Sell
-11,142
Closed -$213K – 3395
2024
Q3 		$213K Buy
+11,142
New +$214K ﹤0.01% 1949

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

HRT Financial's CTNM Position: Q2 2026 in Review

HRT Financial sold out of Contineum Therapeutics (CTNM) in Q2 2026, closing a stake of 22,170 shares — an estimated $289K sold.

HRT Financial first reported a position in CTNM in Q3 2024 and held it in 2 quarters. The position peaked at $289K in Q1 2026. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • HRT Financial reported no remaining Contineum Therapeutics position as of Q2 2026 after selling out during the quarter.
  • HRT Financial sold 22,170 Contineum Therapeutics shares in Q2 2026, an estimated $289K.
  • HRT Financial first reported a position in Contineum Therapeutics in Q3 2024 and held it in 2 quarters.
  • HRT Financial's Contineum Therapeutics position peaked at $289K in Q1 2026.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.